TITLE

Ophthalmic research and publication in India: Where do we stand?

AUTHOR(S)
Kumar Nayak, Barun
PUB. DATE
June 2010
SOURCE
Indian Journal of Ophthalmology;Jun2010, Vol. 58 Issue 4, p273
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
The author reflects on medical researches made in India. The research conducted by Wong and colleagues describes the challenges met in the development of research in Asian countries. The research made by Thatte and colleagues shows the reasons for the anticipated outsourcing of 65% of Food and Drug Administration (FDA) regulated trials from the U.S. The study conducted by Dhaliwal and colleagues reveals that only 30% of postgraduate theses are published from an Indian university medical college.
ACCESSION #
51699626

 

Related Articles

  • QbD impact minimal so far.  // Pharmaceutical Technology;Aug2010 Supplement, ps14 

    The article focuses on the impact of the U.S. Food and Drug Administration's quality-by-design (QbD) initiative on the nature of the work being requested of and performed by contract development organizations.

  • FDA and clinical investigator conflict of interest. Dickinson, James G. // Medical Marketing & Media;Mar1998, Vol. 33 Issue 3, p12 

    Focuses on the United States Food and Drug Administration, proposal regarding conflicts of interest in the medical research community. What the rule implements; What the rule will propose to clinical investigators; Response to the rule.

  • Another Study Implicates Avandia. Elliott, William T. // Critical Care Alert;March2008 Pharmacology Watch, p1 

    The article presents several issues such as the adoption of the strengthened warning for the stop of smoking drug varenicline (Chantix) by the Food and Drug Administration (FDA) and integration of conventional therapy on weight loss for type 2 diabetics from the Australian study.

  • FDA Wants Tests of New Data Submission Standard. Goedert, Joseph // Healthdatamanagement.com;2/29/2012, p1 

    The article reports on the plan of the U.S. Food and Drug Administration (FDA) to test electronic submission of non-clinical study data using a new standard.

  • FDA Recommendations to Industry Regarding Outsourcing. Swider, Marlen Garcia // BioPharm International;Apr2009 Supplement, p6 

    The article discusses guidance from the U.S. Food and Drug Administration on how to ensure compliance in outsourcing. The economic conditions that affect the capability of drug manufacturers to perform manufacturing operations at their establishments are tackled. The complexity that outsourcing...

  • Erratum to: Introduction to the Special Issue on Tone at the Top. Gunz, Sally; Thorne, Linda // Journal of Business Ethics;Jan2015, Vol. 126 Issue 1, p167 

    The article presents acknowledgements from guest editors Sally Gunz and Linda Thorne who wrote the article in the current issue entitled "Introduction to the Special Issue on Tone at the Top."

  • FDA targets conflicts of interest in clinical studies. Tarlach, Gemma M. // Drug Topics;4/6/98, Vol. 142 Issue 7, p30 

    Reports that in 1998 the United States Food and Drug Administration (FDA) issued a regulation which aims to reduce bias among clinical investigators. How this regulation will operate; When this regulation was issued; Stipulations and requirements of this regulation; Views of critics of this...

  • FDA Expands Clinical Trial Disclosures. GOEDERT, JOSEPH // Health Data Management;Mar2012, Vol. 20 Issue 3, p14 

    The article reports that the U.S. Food and Drug Administration (FDA) will require research subjects in clinical trials to be informed of financial arrangements or prior misconduct of clinical investigators.

  • Novel Therapies, High-Risk Pediatric Research, and the Prospect of Benefit: Learning from the Ethical Disagreements. de Melo-Martín, Inmaculada; Sondhi, Dolan; Crystal, Ronald G // Molecular Therapy;Jun2012, Vol. 20 Issue 6, p1095 

    The article reports that despite recent efforts by the US Food and Drug Administration (FDA) to improve the quality and quantity of clinical research data, two-thirds of drugs prescribed currently to children have not been studied for safety and efficacy in pediatric populations, and information...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics